Reference : Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral bloo...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/6315
Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
English
Vanstraelen, Gaetan mailto [> > > >]
Frere, Pascale mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Ngirabacu, Marie-Christine [> > > >]
Willems, Evelyne mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Fillet, Georges mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
2006
Experimental hematology
34
3
382-8
Yes (verified by ORBi)
International
0301-472X
Netherlands
[en] Antineoplastic Agents/administration & dosage/therapeutic use ; Cyclophosphamide/administration & dosage ; Etoposide/administration & dosage ; Filgrastim/administration & dosage ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma/drug therapy ; Multiple Myeloma/drug therapy ; Transplantation, Autologous
[en] In order to assess the effect of Pegfilgrastim on the duration of neutropenia and clinical outcome of patients after autologous peripheral blood stem cell (PBSC) transplantation, we compared 20 consecutive patients with lymphoma or multiple myeloma receiving a single 6-mg dose of Pegfilgrastim on day 1 posttransplant to an historical control group of 60 patients receiving daily Filgrastim 5 microg/kg starting on day 1 posttransplant. The duration of neutropenia was similar in the Pegfilgrastim group compared with the control group. There were no differences in time to neutrophil, erythroid, or platelet engraftment nor in the incidence of fever and infections. The duration of antibiotic therapy, transfusion support, and time to hospital discharge were similar in the two groups. However, after initial hematopoietic reconstitution, we observed significantly higher values of lymphocytes (e.g., 1,660+/-1,000 versus 970+/-460 on day 80, p=0.0002), neutrophils (e.g., 3,880+/-2,030 versus 2,420+/-1,500 on day 25, p=0.0004), reticulocytes (e.g., 148,160+/-90,590 versus 87,140+/-65,920 on day 25, p<0.0001), and platelets (e.g., 210,700+/-116,090 versus 150,240+/-58,230 on day 55, p=0.0052) up to day 100 in the Pegfilgrastim group compared with the Filgrastim group. These observations had no impact on clinical outcome of the patients after day 30 due to the low incidence of infectious events after engraftment in autologous PBSC transplantation. We conclude that the effect of Pegfilgrastim administrated on day 1 posttransplant is comparable to that of daily Filgrastim on initial hematopoietic reconstitution. The possibly superior effect of Pegfilgrastim on cell counts we observed after initial engraftment should be further tested in a prospective randomized trial.
http://hdl.handle.net/2268/6315
10.1016/j.exphem.2005.11.013

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Neulasta-AutoPBSC-Exp.Hematol.pdfPublisher postprint193.37 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.